Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

3.47USD
4:00pm EDT
Change (% chg)

$0.07 (+2.06%)
Prev Close
$3.40
Open
$3.45
Day's High
$3.58
Day's Low
$3.37
Volume
53,890
Avg. Vol
134,726
52-wk High
$13.27
52-wk Low
$3.15

Latest Key Developments (Source: Significant Developments)

Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial
Thursday, 4 May 2017 08:30am EDT 

May 4 (Reuters) - Oncomed Pharmaceuticals Inc : :Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial.Oncomed Pharmaceuticals Inc - trial will be conducted at five centers in U.S. And is expected to enroll approximately 30 patients..  Full Article

Oncomed reports workforce reduction
Monday, 24 Apr 2017 04:35pm EDT 

April 24 (Reuters) - Oncomed Pharmaceuticals Inc ::Oncomed announces workforce reduction.Oncomed Pharmaceuticals Inc - oncomed will reduce its workforce by approximately 50 percent, resulting in 64 remaining full-time employees.Oncomed Pharmaceuticals Inc - company anticipates having sufficient cash to fund operations through q3 2019.Oncomed Pharmaceuticals Inc - anticipates having sufficient cash to fund operations through q3 2019.Oncomed Pharmaceuticals - expects to realize significant cost savings of about $60 million over next 2 years associated with personnel, operating expenses.Oncomed Pharmaceuticals - estimates one-time severance related charges of $2.6 million related to termination benefits and other related expenses.Oncomed Pharmaceuticals Inc - adjusted guidance for its anticipated 2017 expenses to approximately $90 million.Oncomed Pharmaceuticals Inc - majority of severance-related charges will be paid by end of q2 of 2017.Oncomed Pharmaceuticals Inc - "will also seek to maximize value from potential interest in partnering assets to which it has worldwide rights".  Full Article

Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints
Monday, 17 Apr 2017 08:00am EDT 

April 17 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints.Oncomed Pharmaceuticals Inc - trial did not meet its primary endpoint of progression-free survival or secondary endpoints.Also announces discontinuation of brontictuzumab Phase 1B study.  Full Article

Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept
Monday, 10 Apr 2017 08:02am EDT 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept . Oncomed - Bayer Pharma notified co of decision not to exercise option to license WNT pathway inhibitors vantictumab, ipafricept for strategic reasons . Oncomed - Effective June 2017, co to retain worldwide development & commercialization rights to vantictumab, ipafricept, WNT pathway biologics . Oncomed Pharmaceuticals Inc - small molecule program under companies' collaboration continues without change .Oncomed - will be conducting internal portfolio review and prioritization to determine next steps for all programs, including vantictumab, ipafricept.  Full Article

OncoMed Phase 2 demcizumab pancreatic cancer trial misses primary endpoint
Monday, 10 Apr 2017 08:00am EDT 

OncoMed Pharmaceuticals Inc : OncoMed phase 2 demcizumab pancreatic cancer trial misses primary endpoint . OncoMed Pharmaceuticals Inc says trial did not meet primary endpoint of progression-free survival . OncoMed Pharma -interim median overall survival analysis did not show benefit for demcizumab in combination with abraxane plus gemcitabine versus abraxane . OncoMed Pharmaceuticals Inc says safety data seen in yosemite trial were generally consistent and in line with expectations . OncoMed Pharma -based on lack of benefit over standard-of-care, co will be discontinuing Yosemite clinical trial of demcizumab . OncoMed Pharma - will also discontinue any additional enrollment in other ongoing demcizumab trials, conduct analyses of data from those trials as planned .OncoMed Pharma - remains focused on completing, analyzing results of 2 randomized phase 2 clinical trials, pinnacle, denali, are anticipated in h1 of this year.  Full Article

Oncomed Pharmaceuticals Q4 loss per share $0.60
Wednesday, 8 Mar 2017 04:05pm EST 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.60 . Q4 revenue $6.2 million versus $6.8 million . Oncomed Pharmaceuticals Inc - Oncomed expects operating cash burn to be less than $100 million for full year 2017 . Oncomed Pharmaceuticals Inc - current cash is estimated to be sufficient to fund operations through Q3 of 2018 . Q4 earnings per share view $-0.68 -- Thomson Reuters I/B/E/S .Q4 revenue view $8.9 million -- Thomson Reuters I/B/E/S.  Full Article

OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab
Friday, 20 Jan 2017 08:30am EST 

OncoMed Pharmaceuticals Inc :OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab for the treatment of metastatic colorectal cancer patients.  Full Article

OncoMed announces year-end cash balance and 2017 outlook
Thursday, 5 Jan 2017 08:30am EST 

Oncomed Pharmaceuticals Inc : OncoMed announces year-end cash balance and 2017 outlook . Expects 2017 operating cash burn to be less than $100 million, before considering potential milestones/opt-ins . "Phase 2 clinical trial results for demcizumab and tarextumab are anticipated in first half of year" . "Oncomed could receive more than $170 million in total 2017 partner opt-in payments" .Expects to file an IND in first half of 2017 for Oncomed's wholly owned GITRL-FC (OMP-336B11) trimer program.  Full Article

BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - SEC filing
Friday, 26 Aug 2016 01:32pm EDT 

BVF Inc:BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals as of Aug. 18, 2016 - SEC filing.  Full Article

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 06:23am EDT 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

More From Around the Web